HPK1 Assay Kit

Catalog #
79775
$560 *
Size: 96 reactions
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

The HPK1 Assay Kit is designed to measure HPK1 activity for screening and profiling applications using Kinase-Glo® MAX as a detection reagent.
MBP (Myelin Basic Protein) is a non-specific protein substrate that is used as a "universal substrate" for many in-vitro kinase activity assays.  This protein is targeted by many serine/threonine kinases at conserved amino acids. We use the dephosphorylated version of the MBP substrate in our assays to determine the kinase-mediated phosphorylation of MBP.  Our assays are not suitable for studying autophosphorylation of the kinase due to the presence of the MBP substrate.

Synonyms
MAP4K1, Mitogen-Activated Protein Kinase Kinase Kinase Kinase 1, Hematopoietic Progenitor Kinase 1, MAPK/ERK Kinase Kinase Kinase 1
Product Info
Storage and Usage
Citations
Assay Kit Format
Luminescent
Species
Human
Supplied As
The HPK1 Assay Kit comes in a convenient 96-well format, with enough purified recombinant HPK1 enzyme, HPK1 substrate, ATP, and kinase assay buffer for 100 enzyme reactions.
Materials Required But Not Supplied

Kinase-Glo MAX (Promega #V6071)
Dithiothreitol (DTT, 1 M; optional)
Microplate reader capable of reading luminescence
Adjustable micropipettor and sterile tips
30°C incubator

Format

Catalog #

Components

Amount

Storage

40398

HPK1

3 µg

-80°C

Avoid freeze/ thaw cycles!

79334

5x Kinase assay buffer

1.5 ml

-20°C

79686

ATP (500 µM)

100 µl

-20°C

 

MBP (5 mg/ml)

200 µl

-20°C

79696

96-well plate, white

1

Room Temp.

 

UniProt #
Q92918
Background
HPK1 (MAP4K1) or Hematopoietic progenitor kinase 1 is a hematopoietic cell-restricted member of the Ste20 serine/threonine kinase super family. It is a tissue-specific upstream activator of the MEKK/JNK/SAPK signaling pathway. HPK1 diminishes T cell receptor (TCR) signaling activity and T cell proliferation by phosphorylating the adaptor protein SLP-76, suggesting HPK1 could be a novel target for anti-tumor immunotherapy.
References

1. Wu P, et al., Structure, 2019, 27: 125-133.e4
2. Alzabin S, et al., J. Immunol. 2009, 182: 6187-6194
3. Jakob SM, et al., Blood,  2013, 121(20):4184-4194